Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

Italian police were acting on an arrest warrant from the International Criminal Court, reports say. The "once-in-a-century" find has been unearthed in the ancient Roman city. A huge private ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. Research shows that the drug ...

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its ...

Officials say 10 people were taken to hospital after a chairlift failed at the Astún resort in the Spanish Pyrenees. At least 10 people have been injured when a ski lift failed in northern Spain.

On Monday, H.C. Wainwright analyst Andrew Fein adjusted the price target on Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI) to $87.00 from the previous $90.00, while maintaining a Buy rating on the ...

On Tuesday, BofA Securities adjusted its price target for Denali Therapeutics Inc. (NASDAQ:DNLI) shares, reducing it to $30 from the previous $34, while maintaining a Buy rating on the stock. The ...